2-piperidone has been researched along with Kahler Disease in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (8.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (50.00) | 24.3611 |
| 2020's | 5 (41.67) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, W; Li, J; Liu, X; Shi, J; Zhang, Z; Zhao, L; Zhou, Y | 1 |
| Rodriguez-Otero, P; San-Miguel, JF | 1 |
| Amatangelo, M; Bjorklund, CC; Chiu, H; Couto, S; Flynt, JE; Kang, J; Katz, M; Ortiz, M; Pierceall, W; Polonskaia, A; Ren, Y; Thakurta, A; Towfic, F; Wang, M | 1 |
| Atsriku, C; Gaudy, A; Liu, L; MacGorman, K; Palmisano, M; Surapaneni, S; Xue, Y; Ye, Y | 1 |
| Baculi, F; Carmel, G; Condroski, K; Correa, M; Crea, T; Hansen, JD; Hickman, M; LeBrun, L; Liu, W; Lu, CC; Lu, G; Mahmoudi, A; Man, HW; Muller, G; Ruchelman, A; Vocanson, F; Zhang, W | 1 |
| Baculi, F; Carmel, G; Carmichael, J; Cathers, BE; Chamberlain, PP; Daniel, TO; Hickman, M; Khambatta, G; LeBrun, L; Lu, CC; Lu, G; Man, HW; Matyskiela, ME; Muller, G; Pagarigan, B; Riley, M; Satoh, Y; Schafer, P; Zhang, W | 1 |
| Chopra, R; DiMartino, J; Gandhi, AK; Hagner, PR; Hege, K; Li, Y; Papadopoulos, KP; Pourdehnad, M; Rasco, DW; Shih, K; Wei, X | 1 |
| Blay, JY; Cassier, PA; Chawla, S; De Vos, F; de Weger, V; Eskens, F; Frank, R; Gluck, WL; Gounder, MM; Henary, HA; Rasmussen, E; Siegel, D; Soria, JC; Wagner, AJ | 1 |
| Fadeel, B; Feng, X; Holmlund, T; Zheng, C | 1 |
| Anderson, KC; Carrasco, RD; Chauhan, D; D'Arcy, P; Hu, Y; Linder, S; Ray, A; Richardson, P; Tai, YT; Tian, Z; Wang, X | 1 |
| Brnjic, S; D'Arcy, P; De Cesare, M; Fryknäs, M; Hassan, M; Larsson, R; Linder, S; Lindsten, K; Olofsson, MH; Perego, P; Sadeghi, B | 1 |
| Fireman, BH; Friedman, GD; Selby, JV | 1 |
1 review(s) available for 2-piperidone and Kahler Disease
| Article | Year |
|---|---|
A review on the treatment of multiple myeloma with small molecular agents in the past five years.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Combined Modality Therapy; Deubiquitinating Enzymes; Drug Development; Drug Resistance; Histone Deacetylases; Humans; Ikaros Transcription Factor; Immunomodulating Agents; Models, Molecular; Morpholines; Multiple Myeloma; Phthalimides; Piperidones; Proteasome Inhibitors; Treatment Outcome; Ubiquitin-Protein Ligases | 2022 |
3 trial(s) available for 2-piperidone and Kahler Disease
| Article | Year |
|---|---|
Evaluation of iberdomide and cytochrome p450 drug-drug interaction potential in vitro and in a phase 1 study in healthy subjects.
Topics: Adult; Area Under Curve; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Female; Healthy Volunteers; Heterocyclic Compounds, 4 or More Rings; Humans; Immunologic Factors; Itraconazole; Lupus Erythematosus, Systemic; Male; Microsomes, Liver; Middle Aged; Morpholines; Multiple Myeloma; Phthalimides; Piperidones; Rifampin; Young Adult | 2021 |
A First-in-Human Study of Novel Cereblon Modulator Avadomide (CC-122) in Advanced Malignancies.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Lymphoma, Non-Hodgkin; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Piperidones; Quinazolinones; Ubiquitin-Protein Ligases | 2019 |
Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma.
Topics: Acetates; Adult; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Piperidones; Proto-Oncogene Proteins c-mdm2; Tumor Suppressor Protein p53 | 2020 |
8 other study(ies) available for 2-piperidone and Kahler Disease
| Article | Year |
|---|---|
Iberdomide with dexamethasone: a new backbone for myeloma treatment?
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Multiple Myeloma; Phthalimides; Piperidones | 2022 |
Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Drug Resistance, Neoplasm; Heterocyclic Compounds, 4 or More Rings; Humans; Lenalidomide; Leukocytes, Mononuclear; Morpholines; Multiple Myeloma; Phthalimides; Piperidones; Thalidomide; Tumor Cells, Cultured; Ubiquitin-Protein Ligases | 2020 |
Protein Degradation via CRL4
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Chemistry Techniques, Synthetic; Drug Evaluation, Preclinical; Humans; Ikaros Transcription Factor; Molecular Docking Simulation; Multiple Myeloma; Peptide Hydrolases; Peptide Termination Factors; Phthalimides; Piperidones; Proteolysis; Quantitative Structure-Activity Relationship; Ubiquitin-Protein Ligases | 2018 |
A Cereblon Modulator (CC-220) with Improved Degradation of Ikaros and Aiolos.
Topics: Adaptor Proteins, Signal Transducing; Cell Line, Tumor; Crystallography, X-Ray; DNA-Binding Proteins; Fluorescence Resonance Energy Transfer; Heterocyclic Compounds, 4 or More Rings; Humans; Ikaros Transcription Factor; Lenalidomide; Morpholines; Multiple Myeloma; Peptide Hydrolases; Phthalimides; Piperidones; Protein Binding; Proteolysis; Ubiquitin-Protein Ligases | 2018 |
Proapoptotic effects of the novel proteasome inhibitor b-AP15 on multiple myeloma cells and natural killer cells.
Topics: Adult; Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Caspase 3; Cathepsin D; Cell Line, Tumor; Cells, Cultured; Dose-Response Relationship, Drug; Enzyme Activation; Flow Cytometry; Humans; Killer Cells, Natural; Membrane Potential, Mitochondrial; Mitochondria; Multiple Myeloma; Phosphatidylserines; Piperidones; Poly(ADP-ribose) Polymerases; Protease Inhibitors; Time Factors | 2014 |
A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Endoplasmic Reticulum Stress; Female; Gene Expression Regulation, Neoplastic; Humans; Mice; Multiple Myeloma; Piperidones; Protease Inhibitors; Pyrazines; Ubiquitin Thiolesterase; Up-Regulation | 2014 |
Inhibition of proteasome deubiquitinating activity as a new cancer therapy.
Topics: Animals; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Boronic Acids; Bortezomib; Breast Neoplasms; Carboxypeptidases; Cell Line, Tumor; Disease Models, Animal; Female; Gene Expression Regulation, Enzymologic; Humans; Mice; Mice, Inbred BALB C; Mice, SCID; Microarray Analysis; Multiple Myeloma; Piperidones; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Tumor Suppressor Protein p53; Ubiquitin; Ubiquitin Thiolesterase; Ubiquitination | 2011 |
Screening prescription drugs for possible carcinogenicity: eleven to fifteen years of follow-up.
Topics: Anti-Bacterial Agents; Atropa belladonna; Carcinogens; Drug-Related Side Effects and Adverse Reactions; Erythromycin; Esophageal Neoplasms; Folic Acid; Follow-Up Studies; Gastrointestinal Neoplasms; Lung Neoplasms; Lymphoma, Non-Hodgkin; Multiple Myeloma; Neomycin; Neoplasms; Phenylbutazone; Piperidones; Plants, Medicinal; Plants, Toxic; Polymyxin B; Propantheline; Secobarbital; Sulfathiazoles; Vitamins | 1989 |